Status:
COMPLETED
Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk
Lead Sponsor:
University of Wisconsin, Madison
Collaborating Sponsors:
United States Department of Defense
Conditions:
Breast Cancer Risk
Eligibility:
FEMALE
55-70 years
Brief Summary
Mammographic density is sensitive to estorgen exposure and constitutes a strong intermediate maker of breast cancer risk. We hypothesize that women with higher serum xenoestrogen levels will have grea...
Eligibility Criteria
Inclusion
- 55-70 years of age, Post menopausal
Exclusion
- If they have ever used hormone replacment therapy or have ever used Tamoxifen or Raloxifene, Diag. with breast cancer have had breast implants or have had a mastectomy/
Key Trial Info
Start Date :
July 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
270 Patients enrolled
Trial Details
Trial ID
NCT00839696
Start Date
July 1 2008
End Date
April 1 2010
Last Update
November 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin Hospital
Madison, Wisconsin, United States, 53792